CELL INTELLIGENCE · 肿瘤细胞治疗研究

解析免疫微环境：髓母细胞瘤亚型的精准免疫治疗

Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtypes.

胶质瘤中的 NK 细胞功能障碍：从免疫逃逸到免疫治疗

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.

靶向 GD2 表达恶性肿瘤的免疫治疗策略

Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.

挑战与突破：实体瘤 CAR-T 细胞治疗临床试验的现状与未来前景

Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.

GD2-CAR-T 细胞治疗 H3K27M(+) 弥漫性内生性脑桥胶质瘤：I 期临床试验与机制见解

GD2-CAR T Cell Therapy for H3K27M (+) Diffuse Intrinsic Pontine Glioma: A Phase I Clinical Trial and Mechanistic Insights.

PSMA CAR-T 联合 GD2 CAR-T 治疗复发/难治性胶质瘤的初步探索

Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas.

联合 PSMA CAR-T 与 GD2 CAR-T 细胞疗法在复发/难治性胶质瘤治疗中显示出显著疗效和良好耐受性，且未出现严重不良反应。

CAR-T 疗法治疗中枢神经系统肿瘤的进展

Advances in CAR-T therapy for central nervous system tumors.

工程化诱导神经干细胞联合 GD2 特异性 CAR-NK 对高级别胶质母细胞瘤的治疗效果

Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK.

PBMC 来源的 iNSCs TK 在体外和体内均显示出显著的肿瘤趋向性迁移和对 GCV 的有效抗肿瘤活性。此外，与 GD2NK92 联合使用时，iNSCs TK 的治疗效果显著提高，延长了荷瘤动物模型的中位生存期。

抗 GD2 CAR NK-92 细胞在弥漫性内生型脑桥胶质瘤中的抗肿瘤疗效

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.

我们的研究证明了 GD2-CAR NK-92 细胞用于 DIPG 过继性免疫治疗的潜力和安全性。该疗法的安全性和抗肿瘤效果有待在未来的临床试验中进一步证实。

GD2 CAR-T 细胞联合 Nivolumab 表现出增强的抗肿瘤疗效

GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy.